Original Research Article

A study of Her-2/Neu oncogene expression in benign and malignant endometrial lesions and its association with clinicopathologic variables

Syeda Hajra Fatima¹,*, Shashikala², Vijay Sreedhar², Uzma Viqar³, Ahmed Minhajuddin⁴

¹Dept. of Pathology, National Research Institute of Unani Medicine, Hyderabad, Telangana, India
²Dept. of Pathology, Osmania Medical College, Hyderabad, Telangana, India
³Dept. of Pharmacology, National Research Institute of Unani Medicine, Hyderabad, Telangana, India
⁴National Research Institute of Unani Medicine, Hyderabad, Telangana, India

A R T I C L E  I N F O

Article history:
Received 22-10-2021
Accepted 28-10-2021
Available online 02-12-2021

Keywords:
Endometrial carcinoma
Endometrial Hyperplasia
HER2/neu
prognostic factor

A B S T R A C T

Introduction: Endometrial carcinoma is commonly diagnosed gynaecological malignancy in women and the incidence of endometrial cancer and associated mortality rates have increased in recent years. Endometrial hyperplasia is recognized precursor lesion of endometrial cancer and its timely detection offers an opportunity to prevent the development of endometrial cancer. Her-2/neu oncogene amplification has been implicated in the development and progression of many tumours and its overexpression may be involved in tumorigenesis of endometrial carcinoma as well. The present study was aimed to evaluate Immunohistochemical (IHC) expression of Her-2/neu oncogene in Benign and Malignant Endometrial Lesions and its correlation with clinicopathological features in order to define its potential prognostic significance.

Material and Methods: A total of 62 cases including 20 cases of endometrial hyperplasia and 42 cases of Endometrial Carcinoma were enrolled in the study. Clinical and pathologic information was obtained and recorded. Her-2/neu expression was evaluated by immunohistochemistry (IHC) on paraffin embedded tissue sections with Her-2/neu antibody. Overexpression was defined as complete, membrane, moderate to strong intensity staining in greater than 10% of cells.

Results: Positive HER-2/neu expression is seen in 45% cases of Endometrial Hyperplasia and in 54.76% cases of endometrial carcinoma. The Her-2/neu overexpression was observed in patients with advanced stage (p<0.05), High Grade (p<0.05), myometrial invasion (p<0.05), cervical invasion (p<0.05), and lymph node metastasis (p<0.05).

Conclusion: In the present study Abnormal high Her-2/neu expression was observed in Endometrial carcinoma, correlating with High FIGO stage, high grade, lymph node metastasis, myometrial invasion and cervical invasion, indicating Her-2/neu expression analysis could be an important prognostic factor of Endometrial carcinoma.

1. Introduction

Endometrial carcinoma (EC) is the 6th most commonly diagnosed cancer in women worldwide¹ and the third most common gynaecological malignancy in South-Eastern Asia following cervical and ovarian carcinomas.² The most of the patients have a favourable 5-year relative survival rate if diagnosed at an early stage.³ The overall 5-year survival rate is approximately 96%.³ The disease is rare before 40 years age group and 80 % of the patients are in postmenopausal

For reprints contact: reprint@ipinnovative.com

https://doi.org/10.18231/j.achr.2021.056
2581-5725/© 2021 Innovative Publication, All rights reserved. 255
age at the time of diagnosis. Majority of the carcinomas occurs sporadic with only 5–10% having a hereditary basis. The major risk factors relate to hormonal stimulation of the endometrium in conditions like unopposed Oestrogen therapy, polycystic ovarian disease and oestrogen-producing tumours. Obesity is observed in 50% of patients with endometrial carcinoma, and the risk is linked to disturbances in hormone metabolism related to obesity. The other risk factors include nulliparity, diabetes, hypertension and breast cancer patients treated with tamoxifen therapy (six- to eight-fold increased risk).

Endometrial hyperplasia is diagnosed with the presence of proliferating endometrial glands resulting in increase in gland-to-stroma ratio. Endometrial hyperplasia is a recognized precursor lesion of the most common type of endometrial cancer (endometrioid) and its timely detection offers an opportunity for prevention of endometrial cancer. However the rate of progression depends on factors such as the degree of architectural abnormality and the presence or absence of nuclear atypia. Endometrial hyperplasia is seen most frequently in menopause or postmenopausal women, when there are anovulatory cycles.

The endometrium shows tightly controlled hormone-dependent variation during menstrual cycle and when this tightly controlled system is disturbed it may lead to series of changes which may initiate and promote the progression of endometrial tissue toward malignant phenotype. These changes can be further divided into distinct steps involving activation of oncogenes or other proteins involved in tumor invasion and progression like self-sufficiency in growth signals, insensitivity to growth inhibition, evasion of apoptosis, angiogenesis, invasion and metastasis involving genetic alteration/activation of various oncogenes/other proteins. Oncogenes are usually present in inactive state, and their activation stimulates the process of cell division. Only few oncogenes are known to be altered in endometrial cancer. Amplification and increased expression of oncogene HER-2/neu is observed in 10% - 40% of endometrial carcinomas and its expression correlates with a poor prognosis and more aggressive tumour behaviour.

Her-2/neu is an oncogene located on the chromosome 17; encoding type 1 tyrosine kinase growth factor receptor. Her-2/neu (c-erbB-2) gene expression plays an important role in coordinating the endometrial growth factor receptor signaling network. When Her2/neu gene is expressed normally, it leads to the combination of a few copies of Her-2/neu heterodimers and the Her-2/neu-mediated signalling is weak resulting in a normal cell growth. But Her-2/neu Gene amplification results in 50-100 genes per cell leading to the expression of more than 2,000,000 Her-2/neu proteins per cell in the tissue, instead of the 20,000-50,000 Her-2/neu proteins per cell, leading to increase tyrosine kinase activity which in turn increases mitogenic cell signalling and increase cell proliferation activity and shows anti-apoptotic and neo-angiogenic effects. Her-2/neu oncogene amplification is seen in many human cancers like breast cancer, pancreatic cancer and ovarian cancers and it provides an attractive therapeutic target.

The development of Her-2-targeted therapies has revolutionized the treatment of HER2-positive breast cancer and has significantly improved their outcomes. A humanized monoclonal antibody directed against the extracellular domain of the Her-2 receptor is found to have a significant therapeutic effect in patients with Her-2/neu positive carcinomas as it prevents ligand-independent Her-2 signaling, down regulates Her-2/neu expression and diminishes more active p95–Her-2 form of Her-2. Targeting Her-2/neu may be beneficial for a selected group of patient with endometrial carcinoma showing Her-2/neu overexpression. The present study is aimed to evaluate Her-2/neu protein overexpression in endometrial hyperplasia and carcinoma, its pattern of expression and correlation with histological type, and grade of tumour and clinical stage wherever possible.

2. Materials and Methods

2.1. Materials

1. The present study was conducted in the Department of Pathology, in a Tertiary Cancer Hospital in Hyderabad, retrospectively from January 2010 to June 2012.
2. Immuno-histochemical evaluation of a total 62 cases was conducted who were confirmed to have Endometrial hyperplasia (20 cases) and Endometrial Carcinoma (42 cases) and were obtain from endometrial curettings and hysterectomy specimens which were sent to the Department of pathology, MNJ Cancer Hospital and Research Institute, Hyderabad. The haematoxylin & eosin (H&E) stained slides of the cases were retrieved & screened for confirmation of diagnosis followed by selection of the appropriate paraffin blocks.
3. Endometrial Carcinoma Tumor staging was performed according to the International Federation of Gynaecology Obstetrics (FIGO) staging revised in 2009 and TNM staging system. Demographic and clinical information like age at time of diagnosis, clinical presentation and parity was obtained and recorded.

2.2. Methods

Formalin-fixed, paraffin embedded tissue blocks of each of 62 cases were obtained and all hematoxylin & eosin-stained sections were reviewed, the quality of the material was checked, and the best sections from each specimen were selected. All microscopic slides were reviewed to confirm the pathological diagnosis and grading was done
according to the International Federation of Gynaecology and Obstetrics (FIGO) grading system. Tumour staging was performed according to the FIGO classification and TNM staging system. Patient’s medical records and clinic-pathologic characteristics were reviewed. 3µm sections were taken on positively charged slides for IHC with HER-2/Neu. IHC was performed for HER-2/Neu using standard IHC protocol (DAKO). The Polyexcel HRP (non-biotin, micro-polymer based) DAB Detection system was used with adequate positive and negative controls.

2.3. Interpretation of IHC

Estimation of HER-2/Neu expression was evaluated under light microscope and uniform criteria were used according to College of American Pathologists (CAP) guidelines and criteria used in Badr E. H., et al study. Brown stain of the cytoplasmic membrane was considered positive for IHC Staining.

The intensity of HER-2/Neu staining was scored as: 
0 = No reactivity observed;
+1 = Incomplete membranous staining or complete membranous staining in less than 10% of the tumor cells;
+2 = Moderate intensity; complete membranous staining in more than 10% of the tumour cells;
+3 = Strong staining intensity, complete membrane staining is observed in more than 10% of the tumour cells.

In present study, Scores of 0 or 1+ was considered tumour negative for Her2/neu expression and specimens with 2+or 3+ staining were considered positive for HER-2/Neu antibody overexpression.

2.4. Statistical analysis

The data was entered and analyzed in SPSS. Frequencies and percentages of all the variables were computed. The chi-square test ($X^2$) was used to evaluate the relation between histopathological parameters and immunohistochemical markers. The results were considered statistically significant if the P value was < 0.05

3. Results

3.1. Clinic-pathological characteristic of patients

3.1.1. Clinical presentation

A total 62 (20- hyperplasia & 42- Endometrial carcinoma) cases were included in the current study. The mean age was 50.56 ± 9.95 years, where 6 cases of simple hyperplasia were between age group 35 – 40 years and 4 cases were aged 41-50 years. 5 cases of complex hyperplasia were aged between 35-40 years and 5 cases between 41-50 years.

While majority of patients with endometrial carcinoma (17 cases) were aged between 51-60 years, 13 cases were between 41-50 years, 9 cases are between 61-70 years and 2 cases were above 70 years. (Table 1)

In the present study, most of patients of simple hyperplasia presented with menorrhagia (8 patients), and only 2 patients with polymenorrhea. Majority of patients with Complex hyperplasia presented menorrhagia (7 patients), followed by post-menopausal bleeding (3 patients). In endometrial carcinoma 35 patients (83.33%) presented with postmenopausal bleeding followed by 7 patients (16.6%) with menorrhagia. Regarding parity of patients, majority of patients with endometrial carcinoma were in Parity 2 (20 patients) followed by Parity 1 (10 patients).

3.2. Type and Grade wise distribution of Endometrial Carcinoma

All the carcinomas were graded from I- III according to International Federation of Gynecology and Obstetrics (FIGO) grading system based on the degree of glandular differentiation. 17 cases (40.47%) were in Grade I, 10 cases (23.80%) were in Grade II and 15 cases (35.71%) were in Grade III. Among 42 cases of endometrial carcinoma, 38 cases (90.47%) were of Endometrioid adenocarcinoma (type 1) and 4 cases (9.52%) are of serous adenocarcinoma (type 2).Table 2

3.3. Endometrial Carcinoma staging

The tumour was staged according to TNM staging system based on pathology of primary tumour, lympho -vascular invasion and lymph node assessment and showed 17 cases of Stage I (Tumour confined to the corpus uteri only) of which 4 cases (9.52%) were Stage Ia, 10 cases (23.8%) of Stage Ib and 3 cases (7.14%) of Stage Ic. Followed by 9 cases of Stage II (Tumour invades cervix) of which 4 cases (9.52%) showed Endocervical glandular involvement only (Stage IIa) and 5 cases (11.9%) showed Cervical stromal invasion (Stage IIb).

16 cases were of Stage III (Local and/or regional spread of tumour) of which 13 cases (30.95%) showed Metastases to pelvic and / or para-aortic lymph nodes (Stage IIIc), whereas in 2 cases (4.76%) Tumour invasion into the B/L ovaries was seen and only in single case (2.38%) Vaginal involvement was seen. Table 3

3.4. Immunohistochemical analysis of HER-2/neu expression

All the 62 cases were subjected to Immunohistochemical staining with Her-2 antibody. The intensity of the staining was recorded and graded according to the standard protocol.

Her-2/neu expression analysis of endometrial hyperplasia showed total 9 cases (45%) showing positive Her-2/neu expression (+2 score) of which 3 cases were of simple hyperplasia and 6 cases were of complex hyperplasia. While 11 cases (55%) showing negative for Her-2/neu expression (0, +1 score).
Table 1: Age wise distribution

| AGE (years) | Simple hyperplasia (%) | Complex hyperplasia (%) | Endometrial carcinoma (%) |
|-------------|-------------------------|-------------------------|--------------------------|
| 35-40       | 06 (60%)                | 05 (50%)                | 01 (2.38%)               |
| 41-50       | 04 (40%)                | 05 (50%)                | 13 (30.95%)              |
| 51-60       | 00                      | 00                      | 17 (40.47%)              |
| 61-70       | 00                      | 00                      | 09 (21.42%)              |
| >70         | 00                      | 00                      | 02 (4.76%)               |
| Total       | 10 cases                | 10 cases                | 42 cases                 |

Table 2: Grade wise distribution of Endometrial Carcinoma

| Grade  | No. of patients | Percentage % |
|--------|-----------------|--------------|
| Grade I | 17              | 40.47%       |
| Grade II | 10              | 23.80%       |
| Grade III | 15             | 35.71%       |

Table 3: Stage wise distribution of endometrial carcinoma

| Endometrial carcinoma staging | No. of cases (42) | Percentage (%) |
|-------------------------------|--------------------|----------------|
| Stage Ia                      | 04                 | 9.52%          |
| Stage Ib                      | 10                 | 23.80%         |
| Stage Ic                      | 03                 | 7.14%          |
| Stage IIa                     | 04                 | 9.52%          |
| Stage IIb                     | 05                 | 11.90%         |
| Stage IIIa                    | 02                 | 4.76%          |
| Stage IIIb                    | 01                 | 2.38%          |
| Stage IIIc                    | 13                 | 30.95%         |

Her-2 Immunoexpression analysis in Endometrial carcinoma showed, 23 (54.76%) of the cases showed moderate to strong complete membrane staining in more than 10% of the tumour cells (3+). 16 (38.09%) cases showed weak incomplete membranous staining or complete membranous staining in less than 10% of the tumour cells(1+) and only 03(7.14%) cases showed no membrane staining for HER-2/neu expression. The results are depicted in Table 4.

Based on the histological type of tumour, all the 4 cases of Serous Adenocarcinoma (type 2) showed positive HER-2/neu expression and 19 out of 38 of cases of Endometrioid Adenocarcinoma showed positive HER-2/neu expression. Table 5

3.5. Correlation between histopathological variables and Her-2/neu overexpression

In the present study, Patients with stag I-II disease were compared to those with stage III-IV regarding Her-2/neu expression. Statistically significant relation was reported between Her-2/neu expression and FIGO stage where 16 (94.12%) of patients with stage III-IV expressed positive Her-2/neu while only 07 (28%) of patients in stage I-II demonstrated positive Her-2/neu expression. (p <0.05) According to grade of differentiation, 14 cases with High grade (Endometrioid Grade-3 and serous Adenocarcinoma) showed positive Her-2/neu expression while 09 (33.33%) cases with Low to intermediate grade (Endometrioid Grade-1 and Grade-2) expressed positive Her-2/neu expression, the difference was significant (P <0.05).

Correlation between Her-2/neu expression and lymph node involvement demonstrated significantly higher rates (92.31%) of Her-2/neu expression in patients with lymph node metastases as compared to patients without lymph node metastases (37.93%) (p<0.05). Significant correlation was also reported in myometrial invasion, strong positive Her-2/neu expression was reported in 14 (73.68%) cases with ≥50% myometrial invasion while 09 (39.13%) with <50% myometrial invasion showed positive Her-2/neu expression (P <0.05). Significant correlation (P<0.05) was also reported in cervical invasion, with 17 (77.27%) cases with cervical invasion showing strong positive Her-2/neu expression and 6 (30%) case without cervical invasion showing positive Her-2/neu expression. Table 6

4. Discussion

Endometrial carcinoma is the commonly diagnosed gynecological malignancy in women and the incidence of endometrial cancer and associated mortality rates have increased in recent years. Endometrial hyperplasia is a recognized precursor lesion of endometrial cancer and its timely detection offers an opportunity to prevent the development of endometrial cancer. Atypical endometrial hyperplasia shows features of cytological atypia of the
Table 4: HER-2 Immunoexpression in Endometrial carcinoma

| Diagnosis | HER-2/neu expression assessment |
|-----------|--------------------------------|
|           | Absent (%) | +1 (%) | +2 & +3 (%) |
| Endometrial carcinoma | 03 (7.14%) | 16 (38.09%) | 23 (54.76%) |

Table 5: Correlation of HER-2/neu expression with histological type

| Histopathological type       | No. of cases | Positive HER-2/neu expression (3+ & 2+) |
|-----------------------------|--------------|----------------------------------------|
| Endometrioid Adenocarcinoma | 38           | 19                                     |
| Serous Adenocarcinoma       | 04           | 04                                     |
| Total                       | 42           | 23                                     |

Table 6: Correlation between histopathological variables and Her-2/neu overexpression by IHC in Endometrial carcinoma

| Variables               | Types                        | No. of cases | Negative HER-2/neu expression (0, +1) (percentage) | Positive HER-2/neu overexpression (+3 & +2) (percentage) | X² | P value |
|-------------------------|------------------------------|--------------|--------------------------------------------------|--------------------------------------------------|-----|---------|
| Stage                   | Early (stage IA through IIB) | 25           | 18 72.00%                                        | 07 28.00%                                        | 15.28 | <0.05  |
|                         | Advanced (stage IIIA to IIIC) | 17           | 01 5.88%                                         | 16 94.12%                                        |     |         |
| Grade                   | Low to intermediate (endometrioid G1, G2) | 27           | 18 66.66%                                        | 09 33.33%                                        |     |         |
|                         | High (endometrioid G3, serous) | 15           | 01 6.66%                                         | 14 93.33%                                        |     |         |
| Lymph-node status       | Negative                    | 29           | 18 62.07%                                        | 11 37.93%                                        | 8.63 | <0.05  |
|                         | Positive                    | 13           | 01 7.69%                                         | 12 92.31%                                        |     |         |
| Myometrial invasion     | <50% invasion               | 23           | 14 60.87%                                        | 09 39.13%                                        | 3.71 | <0.05  |
|                         | > 50% invasion              | 19           | 05 26.32%                                        | 14 73.68%                                        |     |         |
| Cervical invasion       | No invasion                 | 20           | 14 70.00%                                        | 06 30.00%                                        |     |         |
|                         | Cervical invasion           | 22           | 05 22.73%                                        | 17 77.27%                                        |     |         |

Fig. 1: A: H&E endometrial glands with complex hyperplasia without atypia (10X); B: HER-2/neu immunoexpression in complex hyperplasia without atypia (40X)

Fig. 2: A: H&E endometrial glands with complex hyperplasia with Atypia (10X); B: HER-2/neu immunoexpression in complex hyperplasia with Atypia (10X)

Fig. 3: A: H&E Well differentiated Endometrioid Endometrial carcinoma (Scanner); B: HER-2/neu immunoexpression in Well differentiated Endometrioid Endometrial carcinoma (40X)

Fig. 4: A: H&E poorly differentiated endometrial adenocarcinoma (Scanner); B: HER-2/neu immunoexpression in poorly differentiated adenocarcinoma (10X).
overexpression in endometrial carcinoma showed 54.76% overexpression. In the study done by Saffari et al, 52% endometrial cancers showed moderate or high HER-2/neu expression. Other studies that reported higher HER-2/neu expression are Cherchi et al.21, Yu et al.22 which showed 55.2% positivity and positive correlation with the grading, myometrial invasion and FIGO stage. In the study done by Yu et al.23 the positive expression rate of Her-2/neu in was 80.6%, significantly higher than that expressed in atypical hyperplasia endometrial tissue (2.8%).

In present study, a significant relationship was observed between Her-2/neu overexpression and FIGO stage of the tumor, lymph node metastases, myometrial invasion and cervical invasion indicating that Her-2/neu is related to most of the prognostic factors of Endometrial Carcinoma. Her-2/neu was strongly positive in 94.12% of patients with stage III-IV endometrioid adenocarcinoma while only 28% of patients in stage I-II demonstrated Her-2/neu expression. 93.33% of Grade 3 tumours showed Her-2/neu overexpression while only 29.63% of Grade 1 & 2 showed Her-2/neu overexpression. The present finding is in accordance with various studies like Eldin et al., Cherchi et al., Yu et al. where poorer the histological differentiation, higher the positive expression of C-erbB-2 was observed.

The present study demonstrated the positive expression of Her-2/neu in patients with lymph node metastasis (92.31%) or depth of myometrial invasion ≥1/2 (73.68%) which was higher than those without lymph node metastasis or depth of myometrial invasion <1/2, indicating Her-2/neu expression increases with aggravation of lymph node metastasis and myometrial invasion. The present study also showed higher expression of Her-2/neu in patients with cervical invasion (77.27%). All above results suggest the statistical significant correlation (p < 0.05) between Her-2/neu overexpression and stage of the tumor, lymph node metastases, myometrial invasion and cervical invasion.

The finding of present study is comparable with Eldin et al.10 study, where 66.7% of Grade 3 tumors, 85% of advanced stage (stage III and IV) showed overexpression, 71% with lymph node metastasis and 70% with >1/2 myometrial invasion showed strong HER-2/neu overexpression. Similarly, Cherchi et al.22 Yu et al.23 also demonstrated a positive correlation between Her-2/neu expressions and grading, lymph node metastasis, myometrial invasion and FIGO stage.

Thus, HER-2/neu overexpression may be an important component in hormone-independent growth and proliferation of endometrium. HER-2/neu overexpression in complex endometrial hyperplasia may be a promising
factor for the prediction of the progression to endometrial carcinoma. The findings in our study support the notion that Her-2/neu overexpression may be a major prognostic factor indicating a more malignant tumour phenotype and Her-2/neu Immunohistochemistry could be incorporated as a prognostic variable in patients with endometrial carcinoma. The patients with endometrial carcinoma showing strong Her-2/neu overexpression may potentially be benefited from Her-2-targeted Herceptin therapy improving their overall survival rate.

5. Conclusion
In conclusion, present study provides evidence of Her-2/neu overexpression in a considerable proportion of the patients with Endometrial carcinoma, demonstrating statistically significant correlation between Her-2/neu expressions and FIGO stage, grading, lymph node metastasis ,myometrial invasion and cervical invasion, indicating Her-2/neu expression analysis could be an important prognostic factors in Endometrial carcinoma and suggesting the opportunity for the possible use of Her-2-targeted Herceptin therapy in selected patients improving their overall survival rate.

6. Conflict of Interest
The authors declare that there are no conflicts of interest in this paper.

7. Source of Funding
None.

References
1. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, Mccluggage WG, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS ONE. 2020;15(4):e0232323. doi:10.1371/journal.pone.0232323.
2. Fatteneth A, Tavassoli P, Devilee. World Health Organization classification of tumours, pathology and Genetics of tumours of Breast and Female Genital Organs; 2003.
3. Makker V, Taylor MH, Aghajanian C. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020;38(26):2981–92. doi:10.1200/JCO.2020.38.26.2981.
4. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64(3):417–20.
5. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment-Review Article. APMIS. 2009;117(10):693–707. doi:10.1111/j.1875-8817.2009.01267.x.
6. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet. 1998;351(9097):155–7. doi:10.1016/S0140-6736(98)05378-2.
7. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49(12):2547–59.
8. Robboy JS, Malcolm C, Anderson, Russell P. Robboy’s Pathology of the female Reproductive Tract; 2002.
9. Odicino FE, Bignotti E, Rossi E. et al HER-2/neu overexpression and amplification in uterine serous papillary carcinomainter. J Clin Oncol. 2004;22:101–6. doi:10.1200/JCO.2004.11.154.
10. Eissa S, Saada MA, El-Sharkawy T. Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrium. Hum Pathol. 1998;29(10):1150–9. doi:10.1016/S0196-8552(98)80043-X.
11. Lortet-Tieulent J, Ferlay J, Bray F. International patterns in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354–61. doi:10.1093/jnci/djx121.
12. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, Mccluggage WG, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS ONE. 2020;15(4):e0232323. doi:10.1371/journal.pone.0232323.
13. Morrisson C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients. J Clin Oncol. 2006;24(15):2376–85.
14. Smolowitz BM, Broadus RR, Burke TW, Sniege N, Soliman PT, Wu W, et al. Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma. J Clin Oncol. 2004;22(15):3126–32. doi:10.1200/JCO.2004.11.1581.
15. Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, et al. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res. 2005;25(4):2921–7.
16. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. J Pathol. 1998;181(10):1150–9. doi:10.1002/(SICI)1096-9896(199808)181:2<1150::AID-JPATH20>3.0.CO;2-T.
17. Eissa S, Saada MA, El-Sharkawy T. Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies. Clin Biochem. 1997;30(3):209–14. doi:10.1016/S0009-9120(97)00092-5.
18. Saffari B, Jones LA, El-Naggar A. Amplification and Overexpression of HER-2/neu (c-erbB2) in Endometrial Cancers: Correlation with Overall Survival. Cancer Res. 1995;55(23):5693–8.
19. Cherchi PL, Marras V, Capobianco G, Ambrosini G, Piga MD, Fadda GM, et al. Prognostic value of p53, c-erbB-2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol. 2001;22(6):451–3.
20. Yu CG, Jiang XY, Li B, Gan L, Huang JF. Expression of ER, PR, C-erbB-2 and Ki-67 in endometrial carcinoma and their relationships...
with the Clinicopathological features. *Asian Pac J Cancer Prev.* 2015;16(15):6789–94. [doi:10.7314/apjcp.2015.16.15.6789]

**Author biography**

**Syeda Hajra Fatima,** Research Officer Pathology  
**Shashikala,** Retd. Associate Pathology  
**Vijay Sreedhar,** Retd. Professor and HOD  

**Uzma Viqar,** Associate Professor  

**Ahmed Minhajuddin,** Director Incharge  

---

**Cite this article:** Fatima SH, Shashikala, Sreedhar V, Viqar U, Minhajuddin A. A study of Her-2/Neu oncogene expression in benign and malignant endometrial lesions and its association with clinicopathologic variables. *IP Arch Cytol Histopathology Res* 2021;6(4):255-262.